What emerging adverse effects are associated with semaglutide (GLP‑1 receptor agonist) and how should clinicians monitor and manage them?

Emerging Adverse Effects of Semaglutide

Clinicians must be aware of several emerging safety concerns with semaglutide, most critically the risk of pulmonary aspiration during anesthesia due to delayed gastric emptying, even after prolonged fasting, along with gastrointestinal complications, acute kidney injury from dehydration, diabetic retinopathy progression, and potential micronutrient deficiencies.

Critical Peri-Operative Risk: Aspiration

The most clinically significant emerging concern is increased risk of regurgitation and pulmonary aspiration during general anesthesia, despite appropriate or even prolonged fasting periods 1.

• Multiple case reports document aspiration events in patients who fasted 10-20 hours for solids, far exceeding standard guidelines 1
• Cases include patients requiring ICU admission and mechanical ventilation after aspiration during routine procedures 1
• Observational studies show increased retained gastric contents in patients undergoing upper endoscopy while on semaglutide 1
• This risk appears related to GLP-1RA-induced delayed gastric emptying, which persists even with extended fasting 1, 2

Management Strategy:

• Consider stopping semaglutide at least 4-14 days before elective procedures requiring anesthesia 1
• Use point-of-care gastric ultrasound when available to assess gastric contents pre-operatively 1
• Consider rapid sequence intubation for higher-risk procedures 1
• Inform anesthesiologists of GLP-1RA use regardless of when last dose was taken 1

Gastrointestinal Adverse Effects

Gastrointestinal disorders represent the most common adverse events, occurring in the majority of patients 3.

• Nausea, diarrhea, constipation, and vomiting are the predominant symptoms 3
• Most GI symptoms are mild to moderate and transient, improving with continued use 3, 4
• Rare but serious: drug-induced pancreatitis (0.27-0.3 cases per 100 patient-years) 3
• Discontinue semaglutide immediately if pancreatitis is suspected (persistent severe abdominal pain radiating to back); do not restart if confirmed 3
• Acute cholecystitis and symptomatic gallbladder disease have been reported 5, 4

Monitoring Approach:

• Educate patients about expected GI symptoms before initiation 4
• Use gradual dose titration to improve tolerance 4
• Monitor for severe or persistent symptoms suggesting pancreatitis or cholecystitis 3, 4

Acute Kidney Injury

Postmarketing surveillance reveals cases of acute kidney injury and worsening chronic renal failure, sometimes requiring hemodialysis 3.

• Most cases occurred in patients experiencing severe nausea, vomiting, diarrhea, or dehydration 3
• Some events reported in patients without known underlying renal disease 3
• Monitor renal function when initiating or escalating doses in patients reporting severe GI reactions 3
• Ensure adequate hydration, particularly during dose escalation 3

Diabetic Retinopathy Complications

Patients with pre-existing diabetic retinopathy face increased risk of retinopathy progression, particularly with rapid glycemic improvement 3.

• In cardiovascular outcome trials, retinopathy complications occurred in 3.0% on semaglutide vs 1.8% on placebo 3
• Risk is substantially higher in patients with baseline retinopathy: 8.2% vs 5.2% placebo 3
• Risk in patients without known retinopathy history remains low: 0.7% vs 0.4% 3
• Recent pharmacovigilance data shows association with vision loss (aROR 1.80) 6

Clinical Action:

• Screen all patients with diabetic retinopathy before initiating semaglutide 3, 2
• Arrange ophthalmologic treatment for active retinopathy before starting therapy 2
• Monitor patients with retinopathy history for progression during treatment 3

Micronutrient Deficiencies

Emerging evidence demonstrates significant nutritional deficiencies developing during GLP-1RA therapy 7.

• Vitamin D deficiency occurs in 7.5% at 6 months and 13.6% at 12 months 7
• Iron depletion is frequent, with 26-30% lower ferritin levels compared to other antidiabetic agents 7
• Over 60% of users consume below estimated requirements for calcium and iron 7
• Vitamin D intake averages only 20% of recommendations 7
• Thiamine and cobalamin deficits increase over time 7
• Protein and calcium insufficiency contribute to lean mass loss 7

Monitoring Strategy:

• Assess baseline nutritional status, particularly in high-risk patients 7
• Monitor vitamin D, iron studies, B12, and thiamine levels periodically 7
• Consider supplementation for identified deficiencies 7
• Ensure adequate protein intake to minimize lean mass loss 7

Psychiatric and Neurologic Signals

Recent pharmacovigilance analysis reveals unexpected associations requiring further investigation 6:

• Suicidal ideation and behavior (aROR 2.52) 6
• Hair loss (aROR 1.42) 6
• Abducens nerve paralysis and positional vertigo reported 5

Monitor patients for mood changes and suicidal ideation, particularly those with psychiatric history 6.

Hypersensitivity Reactions

• Anaphylaxis and angioedema have been reported with GLP-1RAs 3
• Discontinue immediately if hypersensitivity reactions occur 3
• Use caution in patients with history of angioedema to other GLP-1RAs 3

Thyroid C-Cell Tumor Risk

• FDA labeling includes boxed warning for thyroid C-cell tumors based on rodent studies 3
• Contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 3
• Recent reviews suggest this may confer increased risk in humans, though long-term data remain limited 2

Hypoglycemia Risk

Risk of hypoglycemia increases when semaglutide is combined with insulin secretagogues (sulfonylureas) or insulin 3.

• Reduce doses of sulfonylureas or insulin when initiating semaglutide 3
• GLP-1RAs alone do not independently cause hypoglycemia 8
• Semaglutide reduces severe hypoglycemia compared to sulfonylureas and insulin 8

Common Pitfalls to Avoid

• Failing to warn surgical teams about GLP-1RA use before procedures - this is the highest-risk oversight given aspiration potential 1
• Inadequate patient education about expected GI symptoms leading to premature discontinuation 4
• Not monitoring renal function during severe GI symptoms 3
• Missing retinopathy screening in diabetic patients before initiation 3, 2
• Ignoring nutritional assessment in patients on long-term therapy 7
• Not reducing insulin/sulfonylurea doses when starting semaglutide 3